1. Search Result
Search Result
Results for "

EC-1

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

1

Natural
Products

21

Recombinant Proteins

5

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P2740

    EC 1.1.1.1

    Endogenous Metabolite Metabolic Disease
    Alcohol dehydrogenase, Saccharomyces cerevisiae is a dimeric protein in the cytosol of cells. Alcohol dehydrogenase, the key enzyme for alcohol consumption in the body, is the highest expressed in the liver and participates in the detoxification mechanism of environmental alcohol [1].
    Alcohol dehydrogenase, Saccharomyces cerevisiae
  • HY-P2809

    MDH; EC 1.1.1.37

    Endogenous Metabolite Metabolic Disease
    Malate dehydrogenase (EC 1.1.1.37) (MDH) catalyzes the mutual conversion of oxaloacetate and malate, and is associated with the oxidation/reduction of dinucleotide coenzymes [1].
    Malic dehydrogenase, microorganism
  • HY-P2833

    GSH-Px; EC 1.11.1.9

    Glutathione Peroxidase Metabolic Disease
    Glutathione Peroxidase (GSH-Px; EC 1.11.1.9) belongs to the peroxidase family and is commonly used in biochemical research. Glutathione Peroxidase can catalyze reduced glutathione (GSH) to form a disulfide bridge with another glutathione molecule, convert it into oxidized glutathione (GSSG), and react with hydrogen peroxide or lipid peroxide reaction, reducing it to H2O. Glutathione Peroxidase is an effective antioxidant against oxidative stress [1].
    Glutathione Peroxidase
  • HY-125862

    EC 1.6.4.2; GR

    Calcineurin Reactive Oxygen Species Cardiovascular Disease Neurological Disease
    Glutathione reductase, baker's yeast (EC 1.6.4.2) is a reductase. Glutathione reductase, baker's yeast eliminates intracellular ROS. Glutathione reductase, baker's yeast reduces oxidized glutathione (GSSG) to reduced glutathione (GSH) using NADPH as an electron donor. Glutathione reductase, baker's yeast exerts antioxidant activity. Glutathione reductase is mainly used to study diseases associated with oxidative stress, such as Parkinson's disease and sickle cell anemia [1] .
    Glutathione Reductase, baker's yeast
  • HY-10532
    SRT 1720
    40+ Cited Publications

    Sirtuin Autophagy Metabolic Disease
    SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
    SRT 1720
  • HY-124037
    SRT 1460
    5 Publications Verification

    Sirtuin Cancer
    SRT 1460, a potent Sirtuin-1 (SIRT1) activator with an EC1.5 value of 2.9 μM, shows good selectivity for activation of SIRT1 versus SIRT2 and SIRT3 (EC1.5>300 μM), and is more potent than Resveratrol and the closest sirtuin homologues [1].
    SRT 1460
  • HY-19758A

    Sirtuin Cancer
    Sirtuin modulator 1 is a modulator of SIRTl, a homolog of SIRT3, with EC1.5 of < 1 μM, extracted from patent WO 2010071853 A1, Compound No.4.
    Sirtuin modulator 1
  • HY-N12135

    Others Cancer
    15α-Hydroxy-20-oxo-6,7-seco-ent-kaur-16-en-1,7α(6,11α)-diolide (compound 2) is an enantio-kaurene diterpenoid (ent -kaurene diterpenoid), which can be isolated from Rubescens rubescens. 15α-Hydroxy-20-oxo-6,7-seco-ent-kaur-16-en-1,7α(6,11α)-diolide has cellular activity against EC-1, U87, A549, MCF-7 and HeLa cell lines Toxicity, IC50s are 37.69 μM, 79.362 μM, 80.07 μM, 197.35 μM, 462.13 μM, and 180.09 μM respectively [1].
    15α-Hydroxy-20-oxo-6,7-seco-ent-kaur-16-en-1,7α(6,11α)-diolide
  • HY-122732

    Chloride Channel Cardiovascular Disease Neurological Disease
    OADS is a Chloride channel antiporter (ClC-ec1) inhibitor (IC50: 29 μM). OADS specifically inhibits the ClC-ec1 antiporter but not the ClC-1 channel. OADS can be used for research of osteoporosis and neurodegenerative and cardiovascular diseases [1].
    OADS
  • HY-10532R

    Sirtuin Autophagy Metabolic Disease
    SRT 1720 (Standard) is the analytical standard of SRT 1720. This product is intended for research and analytical applications. SRT 1720 is a selective activator of human SIRT1 with an EC1.5 of 0.16 μM, and shows less potent activities for SIRT2 and SIRT3 with EC1.5s of 37 μM and > 300 μM, respectively.
    SRT 1720 (Standard)
  • HY-101792A
    RG7800 tetrahydrochloride
    5 Publications Verification

    RO6885247 tetrahydrochloride

    DNA/RNA Synthesis Neurological Disease
    RG7800 hydrochloride is an orally active SMN2 splicing modulator, with EC1.5xs of 23 nM and 87 nM for SMN2 splicing and SMN protein; RG7800 hydrochloride has the potential to treat spinal muscular atrophy.
    RG7800 tetrahydrochloride
  • HY-19759
    SRT 2183
    2 Publications Verification

    Sirtuin Apoptosis Cancer
    SRT 2183 is a selective Sirtuin-1 (SIRT1) activator with an EC1.5 value of 0.36 μM [1]. SRT 2183 induces growth arrest and apoptosis, concomitant with deacetylation of STAT3 and NF-κB, and reduction of c-Myc protein levels .
    SRT 2183
  • HY-168712

    Factor Xa Cardiovascular Disease
    FXIa-IN-15 (Compound (S)-10h) is an inhibitor for Factor XIa (FXIa) and plasma kallikrein (PKa) with an IC50 of 0.38 nM and 59.2 nM. FXIa-IN-15 exhibits anticoagulant efficacy, that extends 50% activated partial thromboplastin time (aPTT) with EC1.5X of 0.55 μM [1].
    FXIa-IN-15
  • HY-P2768

    LDH, EC 1.4.1.9

    Endogenous Metabolite Metabolic Disease
    Leucine dehydrogenase, Microorganism (EC 1.4.1.9) can be purified from Bacillus spheroides. Leucine dehydrogenase catalyzed the oxidative deamination of L-leucine, L-valine, L-isoleucine, L-norvaline, L-alpha-aminobutyrate, and L-norleucine, and the reductive amination of their keto analogues [1].
    Leucine dehydrogenase, Microorganism
  • HY-169938

    HDAC Histone Demethylase Apoptosis Cancer
    LSD1/HDAC-IN-2 (Compound 20c) is the inhibitor for LSD and HDAC, that inhibits LSD1, HDAC1, HDAC2, HDAC3, HDAC6, and HDAC8, with IC50s of 39.0, 1.4, 1.0, 1.3, 2.9 and 16.0 nM, respectively. LSD1/HDAC-IN-2 inhibits the proliferation of cancer cells, especially the colorectal cancer cells. LSD1/HDAC-IN-2 arrests the cell cycle at G2/M phase, inhibits cell migration, and induces apoptosis in HCT-116 and HT-29 cells. LSD1/HDAC-IN-2 exhibits antitumor efficacy in mouse model without significant toxicity [1].
    LSD1/HDAC-IN-2
  • HY-10261D

    BIBW 2992 oxalate

    EGFR Autophagy Apoptosis c-Met/HGFR Akt Cancer
    Afatinib (BIBW 2992) oxalate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib oxalate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [1] .
    Afatinib oxalate
  • HY-10261A
    Afatinib dimaleate
    Maximum Cited Publications
    72 Publications Verification

    BIBW 2992MA2

    EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [1] .
    Afatinib dimaleate
  • HY-10261AR

    EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (dimaleate) (Standard) is the analytical standard of Afatinib (dimaleate). This product is intended for research and analytical applications. Afatinib (BIBW 2992) dimaleate is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib dimaleate can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [1] .
    Afatinib (dimaleate) (Standard)
  • HY-10261
    Afatinib
    Maximum Cited Publications
    72 Publications Verification

    BIBW 2992

    EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFR wt, EGFR L858R, EGFR L858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [1] .
    Afatinib
  • HY-10261R

    EGFR Autophagy Apoptosis c-Met/HGFR Akt p38 MAPK Cancer
    Afatinib (Standard) is the analytical standard of Afatinib. This product is intended for research and analytical applications. Afatinib (BIBW 2992) is an orally active, potent and irreversible dual specificity inhibitor of ErbB family (EGFR and HER2), with IC50 values of 0.5 nM, 0.4 nM, 10 nM and 14 nM for EGFRwt, EGFRL858R, EGFRL858R/T790M and HER2, respectively. Afatinib can be used for the research of esophageal squamous cell carcinoma (ESCC), non-small cell lung cancer (NSCLC) and gastric cancer [1] .
    Afatinib (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: